Skip to main content

Skye Bioscience, Inc.

For the period ended Dec 31, 2025. Filed Mar 10, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 10, 2026

SKYE$0.69-30.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

PAGE
PART I
Item 1.Business4
Item 1A.Risk Factors25
Item 1B.Unresolved Staff Comments71
Item 1C.Cybersecurity71
Item 2.Properties72
Item 3.Legal Proceedings72
Item 4.Mine Safety Disclosures72
PART II
Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities73
Item 6.Reserved73
Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations73
Item 7A.Quantitative and Qualitative Disclosures About Market Risk82
Item 8.Financial Statements and Supplementary Data82
Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure82
Item 9A.Controls and Procedures82
Item 9B.Other Information83
Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections83
PART III
Item 10.Directors, Executive Officers and Corporate Governance84
Item 11.Executive Compensation84
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters84
Item 13.Certain Relationships and Related Transactions, and Director Independence84
Item 14.Principal Accountant Fees and Services84
PART IV
Item 15.Exhibits, Financial Statement Schedules85
Signatures
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.